OpenAI Launches GPT-Rosalind, A Frontier AI Model Built For Life Sciences That Outperforms Human Experts On Key Biology Benchmarks
Summary
OpenAI launches GPT-Rosalind, a frontier AI model purpose-built for life sciences that outperforms human experts above the 95th percentile on RNA sequence-to-function tasks, beats competitors on key benchmarks, and is now available in research preview for U.S. Enterprise customers through partnerships with Amgen, Moderna, and the Allen Institute.
Key Points
- OpenAI is launching GPT-Rosalind, a frontier reasoning model purpose-built for life sciences research, targeting workflows in biology, drug discovery, protein engineering, genomics, and translational medicine.
- The model is outperforming competing systems on key industry benchmarks including BixBench and LABBench2, and ranks above the 95th percentile of human experts on RNA sequence-to-function prediction tasks when tested with Dyno Therapeutics.
- GPT-Rosalind is now available as a research preview through a trusted-access program for qualified U.S. Enterprise customers, with a free Life Sciences research plugin for Codex offering access to over 50 scientific databases and tools, and partnerships with organizations including Amgen, Moderna, and the Allen Institute.